Molecular mechanisms for the antiapoptotic action of gastrin

被引:75
作者
Todisco, A
Ramamoorthy, S
Witham, T
Pausawasdi, N
Srinivasan, S
Dickinson, CJ
Askari, FK
Krametter, D
机构
[1] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Pediat, Ann Arbor, MI 48109 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2001年 / 280卷 / 02期
关键词
protein kinases; phosphoinositide; 3-kinase; Akt kinase; p38; kinase;
D O I
10.1152/ajpgi.2001.280.2.G298
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Gastrin (G17) has a CCK-B receptor-mediated growth-promoting effect on the AR42J rat acinar cell line. We examined whether G17 inhibits apoptosis induced by serum withdrawal of AR42J cells and CHO-K1 cells stably expressing CCK-B receptors (CHO-K1/CCK-B cells). Cellular apoptosis was measured by flow cytometry and the terminal deoxynucleotidyltransferase-mediated dUTP-FITC nick end-labeling method. Serum withdrawal induced AR42J and CHO-K1/CCK-B cell apoptosis. Addition of 10 nM G17 reversed these effects. We examined the action of G17 (10 nM) on phosphorylation and activation of protein kinase B/Akt, a kinase known to promote cell survival. Akt phosphorylation and activation were measured by kinase assays and Western blots with an anti-phospho-Akt antibody. G17 stimulated Akt phosphorylation and activation. G17 induction of Akt phosphorylation was inhibited by the phosphoinositide 3-kinase (PI 3-kinase) inhibitors LY-294002 (10 muM) and wortmannin (200 nM) but not by the mitogen-activated protein kinase kinase 1 inhibitor PD-98059 (50 muM). To study the role of p38 kinase in G17 signaling to Akt, we examined the effect of G17 on p38 kinase activation and phosphorylation using kinase assays and Western blots with an antiphospho-p38 kinase antibody. G17 induced p38 kinase activity at doses and with kinetics similar to those observed for Akt induction. The p38 kinase inhibitor SB-203580 inhibited G17 induction of Akt phosphorylation and activation at a concentration (10 muM) 10-fold higher than necessary to block p38 kinase (1 muM), suggesting the possible involvement of kinase activities other than p38 kinase. Transduction of AR42J cells with the adenoviral vector Adeno-dn Akt, which overexpresses an inhibitor of Akt, reversed the antiapoptotic action of G17. In conclusion, G17 promotes AR42J cell survival through the induction of Akt via PI 3-kinase and SB-203580-sensitive kinase activities.
引用
收藏
页码:G298 / G307
页数:10
相关论文
共 41 条
[1]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[2]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[3]  
Askari FK, 1996, GENE THER, V3, P381
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]  
BRAND SJ, 1988, J BIOL CHEM, V263, P5341
[6]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[7]   AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation [J].
Chan, TO ;
Rittenhouse, SE ;
Tsichlis, PN .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :965-1014
[8]   PANCREATIC TUMORAL CELL-LINE AR42J - AN AMPHICRINE MODEL [J].
CHRISTOPHE, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (06) :G963-G971
[9]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[10]   Gastrin and gastric epithelial physiology [J].
Dockray, GJ .
JOURNAL OF PHYSIOLOGY-LONDON, 1999, 518 (02) :315-324